Follows children with juvenile inflammatory rheumatism over time
Follows children with juvenile arthritis to study treatment safety and benefit.
Plain-language title generated from the registry record
Registry title: Juvenile Inflammatory Rheumatism (JIR) Cohorte
Key facts
- Where
- Casablanca, MoroccoSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with juvenile inflammatory rheumatic diseases. They will be followed over time to see how well immune-suppressing and biological medicines work and how well they are tolerated.
- Age
- Disease began at 18 years old or younger.
- Sex
- All sexes can join.
- Disease stage
- Juvenile inflammatory rheumatic disease. No stage or severity is stated.
Main reasons for not taking part
- No consent from the patient or the legal representative
Read by machine on 9 November 2026.
Where in Morocco
- Hôpital Ibnou RochdCasablanca, MoroccoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Michaël Hofer
- Trial code
- NCT02377245
- Record updated
- 15 June 2023
- Original description
The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.Read full original descriptionShow less
Setting up a Pediatric Cohort for Inflammatory Rheumatic Diseases
The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.
Inclusion: Patients with juvenile inflammatory diseases; Age at onset up to 18 years old; Consent according national codes of ethics and current laws.
Exclusion: Non-consent from patients and/or legal representative.